In recent years, personalized medicine based on genetic information has become increasingly popular. Doctors can now use a person’s DNA to predict possible diseases and choose suitable treatments. However, the question of whether health insurance companies should use genetic data to decide premiums or coverage remains highly controversial. While this practice may seem beneficial for companies, it raises serious ethical concerns.
On the one hand, insurance companies argue that using genetic information helps them calculate risk more accurately. Insurance systems are based on assessing the probability of illness. If a person has a high genetic risk of developing a serious disease, companies may believe it is fair to charge higher premiums. From a business perspective, this approach could prevent financial losses and keep the insurance system stable. In addition, supporters claim that it encourages people to take preventive measures to improve their health.
On the other hand, allowing companies to use genetic data can lead to discrimination and inequality. Genetic information is something people cannot control. If individuals are charged more or denied coverage because of their DNA, it would be unfair and could create social injustice. For example, people with inherited conditions might struggle to afford healthcare, even though they are not responsible for their genetic makeup. Furthermore, there are serious privacy concerns. Genetic data is extremely sensitive, and if it is misused or leaked, it could cause psychological stress and social stigma.
In conclusion, although using genetic information may help insurance companies manage risks, the ethical problems outweigh the potential benefits. Health insurance should focus on providing equal access to healthcare rather than increasing discrimination. Therefore, strict regulations are necessary to protect individuals’ rights and privacy in the era of personalized medicine.